Patents by Inventor Yuannian LI

Yuannian LI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUND FOR REDUCING URIC ACID LEVELS
    Publication number: 20250000865
    Abstract: The present invention provides use of a PDE4 inhibitor (e.g., compound of Formula (I)) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for reducing uric acid level, preventing an increased uric acid level in an individual, and treating, preventing, or alleviating a disease, disorder, or condition (for example, gout, hyperuricemia) associated with an increased uric acid level in an individual.
    Type: Application
    Filed: November 11, 2022
    Publication date: January 2, 2025
    Inventors: Yuannian LI, Jinyu CHEN, Qinghua ZHU, Qian ZHU
  • Anti-SARS-CoV-2 neutralizing antibodies
    Patent number: 11359007
    Abstract: The present disclosure provides novel neutralizing antibodies against SARS-COV-2, and the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: June 14, 2022
    Assignee: NEWSOARA BIOPHARMA CO., LTD.
    Inventors: Yuannian Li, Wenyi Wang
  • Expression vector for anti-SARS-CoV-2 neutralizing antibodies
    Patent number: 11312760
    Abstract: The present disclosure provides recombinant expression vectors expressing a novel neutralizing antibodies against SARS-COV-2, or the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: April 26, 2022
    Assignee: NEWSOARA BIOPHARMA CO., LTD.
    Inventors: Yuannian Li, Wenyi Wang
  • ANTI-SARS-COV-2 NEUTRALIZING ANTIBODIES
    Publication number: 20220073594
    Abstract: The present disclosure provides novel neutralizing antibodies against SARS-COV-2, and the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided.
    Type: Application
    Filed: August 2, 2021
    Publication date: March 10, 2022
    Inventors: Yuannian LI, Wenyi WANG